Unknown

Dataset Information

Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.


ABSTRACT:

Background

Despite the increased risk for pulmonary hypertension in children with Down syndrome, the response to treatment with targeted therapies for pulmonary hypertension in these patients is not well characterized. The Sildenafil in Treatment-naive children, Aged 1-17 years, with pulmonary arterial hypertension (STARTS-1) trial was a dose-ranging study of the short-term efficacy and safety of oral sildenafil in children with pulmonary arterial hypertension. We assessed the safety and efficacy of oral sildenafil in children with Down syndrome and pulmonary arterial hypertension.

Methods

This was a post-hoc analysis of children with Down syndrome and pulmonary arterial hypertension enrolled in the STARTS-1 trial. Mean pulmonary arterial pressure (mPAP), pulmonary vascular

SUBMITTER: Beghetti M 

PROVIDER: S-EPMC5496590 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature